Minnesota orthopaedics device startup Conventus Orthopaedics announced Monday that the U.S. Food and Drug Administration has approved its minimally invasive treatment for repairing wrist fractures.
The Conventus Distal Radius Surgical System is a self-expanding implant that requires small incisions and is able to reduce “surgical trauma by as much as 80 percent compared to traditional plate and screw fixation techniques,” according to a news release. Because it doesn’t touch the region around the wrist, the DRS implant “preserves soft tissues around the fracture to minimize stiffness, swelling and pain.”
A clinical study of 60 patients in Europe found that fracture healing was confirmed 12 weeks following the DRS implant was inserted into the wrist and for some patients, it was little as six weeks.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
“The introduction of the Conventus DRS Implant will allow orthopedic surgeons to treat a broad range of distal radius fractures in a much less invasive manner without sacrificing stability of the repair,” said Randip Bindra, an orthopedic surgeon in Chicago. We are very eager to begin using this novel technology to improve patient care for this commonly occurring traumatic injury”
Conventus Orthopaedics recently made a regulatory filing that shows the company is seeking $2 million. Spray Venture Partners and TPG Biotech are two investors in the company.
The company is chasing a potential $250 million market in the U.S. based on 40 percent of the ovarall775,000 distal radius fractures that occur annually that needed surgery, said Paul Hindrichs, CEO of Conventus Orthopaedics in an email.
